Mia Dubravcic Dosen

Dr. Mia Dubravcic Dosen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
MPMislav Puljevic
Mislav Puljevic
ECEugen Ciglenecki
Eugen Ciglenecki
VPVedran Pašara
Vedran Pašara
IPIvan Prepolec
Ivan Prepolec
MDMia Dubravcic Dosen
Mia Dubravcic Dosen
VVVedran Velagic
Vedran Velagic
Background: Implantable cardioverter defibrillators (ICDs) have significantly reduced the incidence of sudden cardiac death in patients with heart failure, particularly those with ischemic heart disease. However, the impact on overall mortality remains controversial, especially in non-ischemic heart failure patients. The Danish Study to Assess the Efficacy of ICDs in Patients with Non-Ischemic Systolic Heart Failure (DANISH) trial and subsequent studies have questioned the efficacy of ICDs in this population, particularly among older patients. The present study aimed to evaluate survival outcomes and predictors in a Croatian cohort of patients with an ICD or cardiac resynchronization therapy defibrillator (CRT-D) device. Methods: This retrospective cohort study analyzed data from 614 patients who received an ICD or CRT-D device at KBC Zagreb between 2009 and 2018. Patient data, including demographic information, device indication, and clinical parameters, were collected at the time of implantation. Follow-up data were systematically recorded to assess device activation and survival outcomes. Statistical analyses included a detailed descriptive analysis, Kaplan–Meier survival estimates, and Cox regression models. Results: The cohort consisted predominantly of males (83.4%), with a mean age of 58.7 years. Most had reduced left ventricular ejection fraction (mean 31.4%) and were classified as New York Heart Association (NYHA) class II or III. Over a median follow-up of 48.4 months, 36.6% of patients died. Device activation occurred in 30.3% of patients, with appropriate activation observed in 88.2% of these cases. Cox regression identified age, non-sustained ventricular tachycardia (NSVT), and decompensation history as significant survival predictors. Conclusions: This study confirmed that appropriate device activation improved survival in patients with an ICD/CRT-D. Age, NSVT, and history of decompensation were key predictors of device activation and survival outcomes. These findings underscore the need for individualized patient assessment when considering inserting ICDs, particularly in non-ischemic heart failure patients. Further research is needed to refine clinical guidelines and optimize patient selection for ICD therapy.

8 January 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
MPMislav Puljevic
Mislav Puljevic
PRPetra Grubić Rotkvić
Petra Grubić Rotkvić
MDMia Dubravcic Dosen
Mia Dubravcic Dosen
AŠAndrija Štajduhar
Andrija Štajduhar
MKMajda Vrkić Kirhmajer
Majda Vrkić Kirhmajer
Intermittent claudication (IC) is the most frequent symptomatic manifestation of lower-extremity peripheral artery disease (PAD). Supervised exercise therapy (SET) and endovascular revascularization (ER) are established treatments, but their relative and combined effects on health-related quality of life (HRQoL) remain. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing SET, ER, and ER+SET, with HRQoL as the primary outcome. Methods: Following PRISMA 2020, PubMed, Embase, and CENTRAL were used in December 2024. Eligible RCTs enrolled with IC (excluding critical limb-threatening ischemia) and reported validated HRQoL outcomes at ≥3 months. Two reviewers independently extracted data and assessed risk of bias using the Cochrane RoB 2.0 tool. Random-effects meta-analyses pooled standardized mean differences (SMDs) for HRQoL and mean differences (MDs) for walking distance. Results: Five RCTs (n = 728) were included. Compared with optimal medical therapy, both SET and ER improved HRQoL and walking distance. At 12 months, no significant effect was observed between SET and ER (SMD 0.02; 95% CI: −0.18 to 0.22). ER+SET was superior to SET alone (SMD 0.35; 95% CI: 0.12–0.57). Beyond 24 months, improvements were sustained with SET but attenuated with ER, accompanied by higher reintervention rates in ER-containing arms (approximately 20–30% by 2 years). Adverse events were rare (<1%). Conclusions: Given moderate-certainty evidence (GRADE), SET should remain the first-line therapy for intermittent claudication because it provides durable improvements in patient-centered outcomes with minimal harm. Endovascular revascularization (ER) can provide faster symptom relief, but its long-term benefits are constrained by restenosis and repeat procedures, particularly in femoropopliteal disease.

1 November 2018 in Cardiologia Croatica
Verified
Journal Article
Closed access
HJHrvoje Jurin
Hrvoje Jurin
JSJure Samardžić
Jure Samardžić
SPSaša Pavasović
Saša Pavasović
MDMia Dubravcic Dosen
Mia Dubravcic Dosen
MPMarijan Pašalić
Marijan Pašalić
DMDavor Miličić
Davor Miličić

1 November 2018 in Cardiologia Croatica
Verified
Journal Article
Closed access
MDMia Dubravcic Dosen
Mia Dubravcic Dosen
DLDaniel Lovric
Daniel Lovric
MPMarijan Pašalić
Marijan Pašalić
VLVlatka Reskovic Luksic
Vlatka Reskovic Luksic
KGKristina Gašparović
Kristina Gašparović
JHJadranka Šeparović Hanževački
Jadranka Šeparović Hanževački

1 October 2025 in Cardiologia Croatica
Verified
Journal Article
Closed access
NJNikolina Jupek
Nikolina Jupek
MDMia Dubravcic Dosen
Mia Dubravcic Dosen
IJIvana Jurca
Ivana Jurca
MPMislav Puljevic
Mislav Puljevic
DPDražen Perkov
Dražen Perkov
MKMajda Vrkić Kirhmajer
Majda Vrkić Kirhmajer

1 March 2020 in Cardiologia Croatica
Verified
Journal Article
Closed access
BSBoško Skorić
Boško Skorić
Josko BulumJosko Bulum
Josko Bulum
HJHrvoje Jurin
Hrvoje Jurin
KBKristina Maric Maric Besic
Kristina Maric Maric Besic
MČMaja Čikeš
Maja Čikeš
DMDavor Miličić
Davor Miličić